Blueprint Medicines (NASDAQ:BPMC) Now Covered by Analysts at Jefferies Financial Group

Investment analysts at Jefferies Financial Group started coverage on shares of Blueprint Medicines (NASDAQ:BPMC - Get Free Report) in a research report issued to clients and investors on Monday, MarketBeat Ratings reports. The brokerage set a "buy" rating and a $135.00 price target on the biotechnology company's stock. Jefferies Financial Group's price target points to a potential upside of 52.16% from the stock's previous close.

Several other equities research analysts also recently issued reports on BPMC. Wedbush reaffirmed an "outperform" rating and set a $128.00 price target on shares of Blueprint Medicines in a report on Friday, February 28th. Needham & Company LLC restated a "buy" rating and set a $133.00 target price on shares of Blueprint Medicines in a research note on Thursday, February 13th. HC Wainwright reiterated a "buy" rating and issued a $135.00 price target on shares of Blueprint Medicines in a research note on Friday, February 14th. Guggenheim restated a "buy" rating on shares of Blueprint Medicines in a research report on Wednesday, December 11th. Finally, JPMorgan Chase & Co. boosted their price objective on Blueprint Medicines from $126.00 to $129.00 and gave the stock an "overweight" rating in a report on Tuesday, February 4th. Two analysts have rated the stock with a sell rating, six have given a hold rating, fifteen have given a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus price target of $124.95.

Remove Ads

Blueprint Medicines Stock Up 0.3 %

Shares of BPMC stock traded up $0.25 during trading on Monday, reaching $88.72. The company's stock had a trading volume of 1,840,670 shares, compared to its average volume of 710,609. The business has a fifty day moving average price of $99.45 and a 200-day moving average price of $93.92. Blueprint Medicines has a one year low of $80.68 and a one year high of $121.90. The company has a quick ratio of 2.80, a current ratio of 2.85 and a debt-to-equity ratio of 1.15. The company has a market cap of $5.67 billion, a price-to-earnings ratio of -82.15 and a beta of 0.58.

Blueprint Medicines (NASDAQ:BPMC - Get Free Report) last announced its quarterly earnings results on Thursday, February 20th. The biotechnology company reported ($0.79) EPS for the quarter, missing analysts' consensus estimates of ($0.68) by ($0.11). Blueprint Medicines had a negative net margin of 13.19% and a negative return on equity of 77.49%. Analysts anticipate that Blueprint Medicines will post -1.28 earnings per share for the current year.

Insider Buying and Selling

In other news, CEO Kate Haviland sold 1,446 shares of the business's stock in a transaction dated Tuesday, January 21st. The stock was sold at an average price of $110.24, for a total transaction of $159,407.04. Following the sale, the chief executive officer now directly owns 149,378 shares in the company, valued at approximately $16,467,430.72. The trade was a 0.96 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, insider Ariel Hurley sold 2,250 shares of the company's stock in a transaction that occurred on Monday, January 13th. The shares were sold at an average price of $100.00, for a total value of $225,000.00. Following the completion of the transaction, the insider now directly owns 14,967 shares of the company's stock, valued at $1,496,700. This represents a 13.07 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 29,334 shares of company stock worth $3,103,512 in the last 90 days. Insiders own 4.21% of the company's stock.

Institutional Trading of Blueprint Medicines

Institutional investors have recently modified their holdings of the business. Avoro Capital Advisors LLC acquired a new position in Blueprint Medicines during the 4th quarter worth about $103,356,000. Wellington Management Group LLP raised its position in shares of Blueprint Medicines by 22.5% during the third quarter. Wellington Management Group LLP now owns 3,964,610 shares of the biotechnology company's stock worth $366,726,000 after acquiring an additional 729,055 shares during the last quarter. Norges Bank acquired a new position in shares of Blueprint Medicines in the fourth quarter worth approximately $62,028,000. State Street Corp boosted its holdings in Blueprint Medicines by 16.2% in the third quarter. State Street Corp now owns 2,765,702 shares of the biotechnology company's stock valued at $255,827,000 after acquiring an additional 385,818 shares during the last quarter. Finally, Jennison Associates LLC bought a new stake in Blueprint Medicines in the fourth quarter valued at approximately $31,417,000.

Blueprint Medicines Company Profile

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.